Department of Histology and Embryology, Basic Medical College of Jilin University, Changchun, China.
Stem Cells Dev. 2021 May 1;30(9):459-472. doi: 10.1089/scd.2020.0198.
Corona virus disease 2019 (COVID-19) refers to a type of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Sixty million confirmed cases have been reported worldwide until November 29, 2020. Unfortunately, the novel coronavirus is extremely contagious and the mortality rate of severe and critically ill patients is high. Thus, there is no definite and effective treatment in clinical practice except for antiviral therapy and supportive therapy. Mesenchymal stem cells (MSCs) are not only characterized by low immunogenicity and homing but also have anti-inflammatory and immunomodulation characteristics. Furthermore, they can inhibit the occurrence and development of a cytokine storm, inhibit lung injury, and exert antipulmonary fibrosis and antioxidative stress, therefore MSC therapy is expected to become one of the effective therapies to treat severe COVID-19. This article will review the possible mechanisms of MSCs in the treatment of severe COVID-19.
2019 年冠状病毒病（COVID-19）是由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）感染引起的一种肺炎。截至 2020 年 11 月 29 日，全球已报告 6000 万例确诊病例。不幸的是，新型冠状病毒传染性极强，重症和危重症患者的死亡率很高。因此，临床上除了抗病毒治疗和支持治疗外，尚无明确有效的治疗方法。间充质干细胞（MSCs）不仅具有低免疫原性和归巢性，而且具有抗炎和免疫调节特性。此外，它们可以抑制细胞因子风暴的发生和发展，抑制肺损伤，并发挥抗肺纤维化和抗氧化应激作用，因此 MSC 治疗有望成为治疗严重 COVID-19 的有效方法之一。本文将综述 MSCs 治疗严重 COVID-19 的可能机制。
